Isolation of circulating tumor cells and detection of EGFR mutations in patients with non‑small‑cell lung cancer
Qi Zhang(Jiamusi University), Shucai Zhang(Northeastern University), Hongtao Zhang(Chinese Academy of Sciences), Jinghui Wang(Capital Medical University), Zhuohong Yan(Capital Medical University), Ling Yi(Capital Medical University), Jingying Nong(Capital Medical University), Zhidong Liu(Capital Medical University), Xin Gao
Cited by 20
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
|Journal of the National Comprehensive Cancer Network|2021|532